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Abstract Data demonstrating the efficacy of hyaluronic
acid (HA)-based mesotherapy for skin rejuvenation are
scarce. The aim of the study is to assess the efficacy of non-
reticulated HA-based mesotherapy on skin elasticity and
complexion radiance. 55 women with cutaneous ageing
signs included in the Full Analysis Set (FAS) population
blindly received intradermal micro-injections (50 9
0.02 mL) of non-cross-linked HA filler with mannitol
(Glytone 1, HA concentration: 14 mg/g) in one cheek and
saline physiological solution in the other according to
hemifacial randomisation in 3 monthly sessions. Elasticity
(E1 and E2 stiffness parameters) and dermis thickness were
measured by cutometry and 20 MHz echography, before
(D0) treatment and 1 (1M) and 3 months (3M) after the last
injection. A trained panel blindly scored skin complexion
radiance from standardised and calibrated photographs,
using 100 mm analogue scales. In the FAS population,
only HA filler significantly decreased E1 at 1M (-10.9 %,
p = 0.026) and 3M (-10.5 %, p = 0.035) compared with
D0; its effect versus the control tended to be more persis-
tent, with a difference between treatments at 3M close
to significance (p = 0.063). E2 also decreased at 1M
(-8.2 %, p = 0.027 in the per protocol population,
n = 53) and 3M after HA-treatment only. Dermis thick-
ness significantly increased after HA-treatment at 1M
(?3.4 %, p = 0.028) and 3M (?4 %, p = 0.008), and
after control-treatment at 1M only (?2.5 %, p = 0.015).
The HA filler significantly improved complexion radiance
at 3M compared with the control (p = 0.012) and for 51 %
of subjects, their skin status. Non-reticulated HA-based
mesotherapy significantly and sustainably improves skin
elasticity and complexion radiance.
Keywords Mesotherapy  Hyaluronic acid  Dermis
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Introduction
With age and UV exposure, skin undergoes morphologic
and mechanical changes that manifest as wrinkling, sag-
ging, loss of elasticity and dryness [9]. In particular,
decreased synthesis of collagen and elastin and their
increased degradation, reduced proliferative capacity of
fibroblasts and perturbations in the organisation of elastic
fibre network lead to alterations in the mechanical prop-
erties of the skin with reduced resilience and elasticity [10,
19]. Advances in the knowledge of the biochemical
mechanisms associated with ageing have led to the devel-
opment of different approaches to reduce and repair its
untoward effects [15], particularly by using minimally
invasive procedures.
Originally developed to treat vascular and lymphatic
disorders, mesotherapy has recently been used for skin
rejuvenation. The method consists in multiple and micro-
dosed injections of bioactive products into the skin to
increase its hydration and reconstruct an optimal physio-
logical environment for the fibroblasts. It is aimed in
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particular at enhancing cell activity and synthesis of col-
lagen, elastin and hyaluronic acid (HA) [11]. The most
common formulation of mesotherapy for facial skin reju-
venation includes repetitive injections of a multivitamin
solution in the superficial dermis [4]. However, among the
products available for skin rejuvenation by mesotherapy,
HA plays an important role in the hydration of the extra-
cellular space due to its ability to attract water molecules
and it is thought to create the physiological conditions in
the extracellular matrix for proliferation, migration and
organisation of dermal cells [8]. Clinical experience of skin
rejuvenation by HA-based mesotherapy suggests this
technique is safe inasmuch as it is performed by a trained
physician, who follows safe-injection practices with
appropriate aseptic techniques to prevent the risk of
infection related to inadequate safety measures. Further-
more, several studies suggest it can improve skin hydra-
tion, firmness and viscoelastic properties [12, 13, 16].
However, published results from clinical studies demon-
strating the efficacy of this approach in improving visco-
elastic mechanical properties of the skin are scarce.
The main objective of this study was therefore to assess
the effect of intradermal microinjections of a non-cross-
linked HA-based mesotherapy product with mannitol
(Glytone professional 1), on mechanical properties of
facial skin compared with a control product in subjects
displaying mild to moderate cutaneous ageing signs. With
this aim, we performed measurements by cutometry of
mechanical parameters at the dermis level, which is
assumed to be the main structure involved in viscoelastic
mechanical properties of the skin [17, 18], and we mea-
sured the thickness of the dermis as a secondary endpoint.
Other objectives of this study were to compare the effects
of HA filler and control on skin complexion, their efficacy
self-evaluated by the subjects, and their tolerance.
Subjects and methods
This clinical, biometrological, single-blind, randomised
study was carried out at the Centre de Recherche sur la
Peau Pierre Fabre (CRP), Toulouse (France), according to
the ethical principles of the declaration of Helsinki and the
guidelines for Good Clinical Practices (CPMP/ICH/135/
95). The protocol was approved by the Committee for the
Protection of Persons South-West and Overseas III and the
French Agency for the Safety of Health Products (AFSS-
APS). Each volunteer signed a written informed consent.
Subject selection
Female volunteers (30–65 years), of phototypes I–III
according to Fitzpatrick classification, with mild to
moderate cutaneous ageing signs (mild to visible dehy-
dration, mild to marked sagging/slackening, sallow and/or
olive-greenish complexion, no wrinkles to wrinkles at rest
and fine lines on the surface) on the face were included.
Non-menopausal women had to be under effective con-
traception since at least 2 months before inclusion and had
to have negative pregnancy test results at inclusion and
each mesotherapy session. Menopause diagnosis was to be
confirmed in menopausal women. Subjects presenting the
following criteria were not included: pregnant or breast-
feeding women, any cutaneous pathology of infectious,
inflammatory, viral and vascular type affecting the face,
auto-immune and granulomatous pathologies, diabetes,
Osler’s endocarditis, wound healing disorders, allergy
history to HA or any ingredient of the test product or to any
other product used in the study (Anesderm and Septeal,
Pierre Fabre Dermatologie, Boulogne-Billancourt, France;
Glytone Suncare and Glytone Post-Op, Pierre Fabre
Dermatologie Esthetique, Boulogne-Billancourt, France).
Other criteria for non-inclusion were the regular use of
hormone or systemic (retinoid–based products, immuno-
suppressants, steroid anti-inflammatory drugs) or local
(highly active topical corticoids) treatments that could
influence the study results within the 3 months before
inclusion, any peeling within the 2 years before inclusion,
and any mesolift, lifting, botulinum toxin treatment, HA or
other filler injections, previous facial surgery, remodelling
or ablative laser procedures within the year before
inclusion.
Treatments
The study product was a HA injectable solution (Glytone
1 professional, Merz Pharmaceutical GmbH, Frankfurt,
Germany) consisting of 14 mg/mL non-animal non-retic-
ulated HA in phosphate sodium thus providing a viscosity
suitable for microinjections and increasing the half-life of
the molecule. The HA injectable solution contains glycerol,
a strong moisturising agent which also plays a role in skin
elasticity and potentiates the action of HA, and mannitol
which in particular is known for limiting the degradation of
HA by free radicals through its antioxidant action. The
product was provided in a pack of two pre-filled sterile
1-mL glass syringes supplied with two 30G  needles.
Physiological saline solution (Aguettant) was used as a
control product.
Study design
The study consisted of three injection sessions at monthly
intervals and three assessment visits, the first one 14 days
before the first injection (D0), the second 1 month (1M)
after the last injection session and the third 3 months (3M)
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after the last injection session. The same trained investi-
gator administered HA and control products to all subjects.
One hour before each injection session, the subject applied
a topical local anaesthetic cream (Anesderm) on the face.
After having removed the cream, the whole face was then
thoroughly cleaned with a disinfecting lotion (Septeal).
During each treatment session, the subject randomly
received about 50 9 0.02 mL of study product in one side
of the face and the same amount of control product in the
other side, to allow intra-individual comparison and thus
overcome the problem of inter-individual variations in skin
status. Both products were injected manually into the lower
part of the cheek, at the level of the dermis/epidermis
junction or/and the superficial dermis using the gold stan-
dard serial puncture technique [21], as described by Iorizzo
et al. [11]. A pattern was applied to the skin to precisely
mark injections points, thus allowing reproducibility of
serial injections at each time-point. The intervention was
single blinded, as the subject was not informed of the
injection side of the study product. The difference in vis-
cosity between the study and control products did not allow
the investigator performing the injections to be unaware of
treatment assignments. Then, the investigator massaged the
injection sites to ensure the placement of the product, and
reminded the subject of precautions to follow after injec-
tion (no makeup during the following 12 h, no exposure to
extreme temperatures). The subjects had then to apply a
soothing cream (Post-op Glytone) twice a day during the
five following days. They were also instructed to avoid sun
exposure during the study and were provided a sunscreen
(Glytone Suncare) to apply in case of exposure.
Skin elasticity and dermis thickness measurements
Skin elasticity was measured using a Cutometer MPA580
(Courage & Khazaka, Cologne, Germany). The device
generated negative pressure of up to 100 mbar at a rate of
20 mbar/s sucking up the skin into a probe of 6 mm
diameter aperture, which was put in contact with the skin
perpendicularly to the surface. When the pressure was
withdrawn at the same rate, the skin returned to its normal
shape. The movement of the skin in and out the probe is
illustrated in a pressure–deflexion curve, which allows the
determination of skin stiffness and viscosity parameters.
These parameters were determined using a nonlinear skin
behaviour model specifically developed by the Pierre Fabre
Skin Research Centre [7] and requiring measurements of
dermis thickness. Dermis thickness was measured by
echography using a high-frequency (20 MHz) ultrasound
scanner (Dermcup, ATYS Medical, Soucieu en Jarrest,
France) [14]. E1 and E2 parameters define the stiffness of
elastin and collagen fibres, respectively, and the more they
decrease the more skin is compliant. Equivalent strain
parameter (eeq) corresponds to the strain necessary for
collagen fibres extension.
Biometrological measurements were performed at two
pre-specified 2 cm areas on both cheeks in controlled
conditions at 20 ± 4 C during the three evaluation visits
following a 15 min rest of the subject.
Skin complexion assessment
Skin complexion was evaluated by a panel of 16 experts
trained to do the quantitative descriptive analysis. Using
this methodology, they had to describe complexion radi-
ance and uniformity with the help of calibrated and
standardised photographs of the hemiface, which were
cropped to only display the treated area of the cheek. In
addition, photographs were rendered anonymous and ran-
domised to allow blind scoring by the panel. The com-
plexion evaluation was based on the identification and the
selection of descriptors for establishing a sensory profile [1,
2]. Fifteen training sessions were necessary to validate
panel performance, i.e. the reproducibility, discrimination
and reliability of the panellists in descriptive tests. The
sensory profile was composed of eight items, one for the
global assessment of complexion radiance and seven for
the multidimensional analysis of complexion: four items
detailed complexion radiance (uniformity, hydration, yel-
low and pink aspects of the complexion) and three items
described general skin complexion (firmness, luminosity/
brightness, and quantity of wrinkles). For each hemiface of
each subject, randomised cropped photographs corre-
sponding to the three evaluation time-points were pre-
sented to the panellists, who blindly scored the eight items
using 100 mm visual analogue scales (e.g. from 0 = not
radiant at all to 100 = very radiant).
Evaluation criteria
Primary efficacy criterion
The change in cutaneous mechanical properties induced by
the product was evaluated by assessing skin elasticity
parameters at the level of the product- and control-treated
hemifaces, at D0 and 1 month after the last session of
mesotherapy (1M).
Secondary efficacy criteria
Change in skin elasticity at the level of the control and
HA-treated hemifaces was also assessed 3 months after the
last session of mesotherapy (3M) to evaluate the persis-
tence of the product effect.
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Change in dermis thickness was also evaluated by
echography at the level of the control and HA-treated areas
on the cheeks at D0, 1 and 3M.
The efficacy of the product was also evaluated on skin
complexion by scoring its radiance and uniformity at the
level of the control and HA-treated hemifaces from
standardised and calibrated photographs at D0, 1 and 3M.
Finally, the subjects self-assessed the global efficacy of
the product after each mesotherapy session and at 1 and 3M
by using a 5-point scale (aggravation, no improvement,
slight, moderate and important global improvement).
Safety assessment
All adverse events (AE) occurring at inclusion and
throughout the study were reported from the first evalua-
tion visit (D0). Local tolerance was evaluated after all
injection visits and at 3M using a 4-point scale from
1 = very good tolerance (no functional or objective
symptom) to 4 = poor tolerance (functional and/or objec-
tive symptoms leading to treatment discontinuation).
Statistical analyses
Statistical analysis was performed by using SAS software.
Quantitative variables were described by number of sub-
jects, mean and standard deviations, median and minimum
and maximum, qualitative variables, by number of subjects
and percentage for both groups of treatment. The main
analysis was carried out on the Full Analysis Set (FAS)
population; secondary analyses were carried out on per
protocol (PP) population.
The main efficacy criterion was assessed by analysis of
covariance (ANCOVA) with the product, site and sequence
factors as fixed effects, the subject factor as random effect
and the baseline as the covariate. When the product effect
was significant, the comparison between control and
product effect was performed at each time-point. The same
analyses were used for the secondary criteria except for
self-assessment of product efficacy, which was analysed at
each time point by the Wilcoxon’s signed rank test. Sig-
nificance level was 5 % for the whole study.
Results
Subjects’ flow and demographic characteristics
A total of 60 women were included in the study. Five
subjects were excluded from efficacy analysis, three
because they did not receive any injection and two because
they were not evaluated for the main efficacy criterion. The
FAS population therefore included 55 subjects (97 %) aged
34–65 years (mean age 52.4 years). Two subjects were
excluded from the PP population due to a major protocol
deviation (hormonal therapy stopped 1 week before
inclusion, inversion of randomisation), which consequently
consisted of 53 subjects aged 34–65 years (mean age
52.1 years). Results were reported for the FAS population
only, except when different results were obtained in the PP
population.
Primary efficacy criterion
Effect of control and HA filler on skin elasticity at 1M
Skin elasticity parameters measured by cutometry at the
level of the control and HA-treated cheek areas in the FAS
population are shown in Table 1. At D0, skin elasticity
parameters were not significantly different between control
and HA-treated cheek areas.
Between D0 and 1M, E1 parameter significantly
decreased by 10.9 % in the HA-treated hemifaces
(p = 0.026), whereas it did not significantly change in the
control hemifaces (-2.3 %, p = 0.260) (Table 1). Com-
pared with D0, HA-based treatment also induced a
decrease in E2 parameter by -6.8 % at 1M, although it
was not significant (p = 0.065) (Table 1). However, when
the product effect was analysed in the PP population, E2
parameter change between D0 and 1M reached statistical
significance (-8.2 %, p = 0.027). By contrast, the control
did not induce any significant change between D0 and 1M,
whatever the population analysed (FAS or PP). Neverthe-
less, the comparison between HA and control treatments
failed to show any significant difference in E1 and E2
parameters (Table 1, FAS population). With regard to eeq
parameter, both HA-based and control treatments induced a
significant increase (?13.5 % p = 0.0002 and ?8.8 %,
p = 0.0014, respectively) at 1M versus D0 in the FAS
population, without significant difference between both
treatment effects (Table 1).
Secondary efficacy criteria
Effect of control and HA filler on skin elasticity at 3M
Results of HA and control treatments on skin elasticity
3 months after the last mesotherapy session in the FAS
population are shown in Table 1. HA effect on skin elas-
ticity persisted 3 months after the end of mesotherapy
sessions with a decrease of E1 and E2 parameters at 3M
compared with D0 by -10.5 % (p = 0.035) and -4.3 %
(p = 0.297), respectively; whereas, the control did not
show any significant effect on E1 and E2 parameters.
Furthermore, compared with the control, HA effect tended
to be more persistent, since the difference between the two
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treatments at 3M was close to significance (p = 0.063).
The remanence of HA effect was also significant on col-
lagen fibre entanglement, with a 10.5 % increase of eeq
parameter at 3M compared with D0 (p = 0.002), whereas
the effect of the control was not significant anymore.
However, the difference in eeq parameter between HA and
control treatments was not significant. The time-effect of
control and HA treatment on dissipation was not
significant.
Effect of control and HA filler on dermis thickness
Results of control and HA filler effects on dermis thickness
before and 1 and 3M after the end of mesotherapy in the
FAS population are shown in Table 2. Compared with D0,
dermis thickness significantly increased 1 and 3M after the
last injection of HA (?3.4 %, p = 0.028 and ?4 %,
p = 0.008, respectively). The control also induced a sig-
nificant increase of dermis thickness at 1M compared with
D0 (?2.5 %, p = 0.015), but this effect did not persist at
3M (1.1 %, p = 0.179). No significant difference was
observed between control and HA effects.
Effect of control and HA filler on complexion
Before the first session of mesotherapy (D0), the scores for
the eight items of skin complexion were not significantly
different between control and HA-treated hemifaces.
HA filler had a significant effect on complexion radiance
at 3M compared with D0 (p = 0.023), and it was signifi-
cantly more efficient than the control, with an improvement
of complexion radiance by ?6.2 % from D0 in HA-treated
hemifaces versus impairment by -2.3 % from D0 in the
control-treated hemifaces (p = 0.012). Among the seven
items describing skin complexion, yellow aspect, and skin
hydration improved 1M after the end of mesotherapy in
HA and control hemifaces (Table 3). Pink aspect also
transiently improved at 1M in the control hemiface
(p = 0.041). However, the effects of the HA filler persisted
at 3M, whereas the control effect was not maintained
(Table 3). HA filler effect on yellow aspect and hydration
tended to be significant at 1M (p = 0.057 and p = 0.088)
and 3M (p = 0.055 and p = 0.076), whereas control effect
was significant at 1M only (p = 0.025 and p = 0.022).
However, no significant difference between control and
HA effects was observed on these parameters.
Table 1 Skin elasticity parameters before (D0) and 1 (1M) and 3 months (3M) after the end of mesotherapy sessions in control- and HA filler
HA product-treated hemifaces in the FAS population
Cutometry parameter (mean ± SD) D0 1M % of change 1M vs D0 3M % of change 3M vs D0
E1 (MPa)
HA product 0.149 ± 0.063 0.133 ± 0.054 -10.9* 0.132 ± 0.053 -10.5*
Control 0.134 ± 0.051 0.131 ± 0.052 -2.3 0.138 ± 0.057 ?4.5
p value NS NS – 0.0634 (SL) –
E2 (MPa)
HA product 0.558 ± 0.175 0.518 ± 0.161 -6.8 0.529 ± 0.174 -4.3
Control 0.551 ± 0.190 0.530 ± 0.161 -4.1 0.544 ± 0.182 -0.7
p value NS NS – NS –
eeq
HA product 0.056 ± 0.017 0.063 ± 0.015 ?13.5*** 0.062 ± 0.014 ?10.5**
Control 0.058 ± 0.013 0.063 ± 0.015 ?8.8** 0.060 ± 0.016 ?3.6
p value NS NS – NS –
Dissipation
HA product 0.751 ± 0.037 0.745 ± 0.054 -0.94 0.755 ± 0.047 ?0.2
Control 0.752 ± 0.038 0.753 ± 0.044 ?0.15 0.754 ± 0.049 ?0.3
p value NS NS – NS –
NS non-significant, SL significance limit
E1 and E2 parameters define elastin and collagen fibres stiffness, respectively, and the more they decrease the more skin is compliant. Equivalent
strain parameter (eeq) corresponds to the strain necessary for collagen fibres extension
* Comparison versus D0, p \ 0.05
** Comparison versus D0, p \ 0.01
*** Comparison versus D0, p \ 0.001
 Comparison versus D0, slightly significant difference, p = 0.065
 Comparison between control and HA product treatments
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Self-assessment of product efficacy
At all time points of evaluation, the percentage of subjects
having perceived an improvement of their skin status in the
HA-treated hemiface compared with the control-treated
one was significantly higher (p B 0.01) (Fig. 1). Ever since
the first month after the first mesotherapy session (2nd
injection visit), 16.5 % of the subjects perceived a mod-
erate to important improvement at the level of the HA-
treated hemiface, whereas they were \2 % to find a
moderate improvement in the control-treated hemiface.
This improvement of the HA-treated side increased with
treatment duration and persisted 3 months after the end of
the third mesotherapy session: a moderate to important
improvement was observed by 34.6 and 32.8 % of subjects
in the HA-treated hemiface, at 1 and 3M, respectively,
versus 9 and 10.9 % of subjects in the control-treated
hemiface.
Safety and tolerance assessment
Among the 57 subjects included in the tolerance study
population, 50 (87.7 %) experienced one or several adverse
effects after injection. Adverse events were generally of
mild or moderate intensity and expected (haematoma,
oedema, papule, erythema or other transient inflammatory
reaction): 46.8 % occurred in the HA-treated hemiface and
25.7 % in the control. The most commonly expected
adverse event was haematoma, both in the HA and control-
treated hemifaces, with a global incidence of 35.7 and
20.5 %, respectively. Four subjects experienced severe
haematoma after injection in the HA-treated hemiface, and
four others reported a non-expected severe adverse effect
(pregnancy, otitis, shoulder tendonitis aggravation, func-
tional ankle impairment), but none was related to the study
product. All expected adverse events disappeared within a
mean time of 5.9 days.
Local tolerance to both products was good to excellent
in 85–100 % of cases throughout the study.
Discussion
This controlled single-blind study using hemifacial treat-
ment randomisation demonstrated the efficacy of a non-
cross-linked HA-based mesotherapy product with mannitol
(Glytone professional 1) in improving dermis mechanical
behaviour and complexion radiance of facial skin with a
3-month remanence. In contrast to the control, intradermal
microinjections of HA filler induced a significant decrease
of E1 and E2 parameters, indicating a decrease of elastin
and collagen fibre stiffness and suggesting that this product
may significantly improve skin compliance. This effect
persisted 3 months after the last mesotherapy injections for
E1 parameter and tended to be significant compared to the
control. Furthermore, HA injections significantly and sus-
tainably increased eeq parameters in contrast to the control,
the effect of which was smaller and did not persist with
time. This suggests that non-reticulated HA-based meso-
therapy may sustainably regain suppleness to the skin and
increase entanglement of its collagen fibres thus restoring
the mechanical behaviour of a young skin.
The significant effect of HA-based mesotherapy on
skin elastic properties was coupled in our study with a
sustained increase in dermis thickness 1 and 3M after the
last mesotherapy session. With the control, a significant
effect was observed at 1M only. This transient dermis
thickening with both treatments at 1M may be explained
by the fact that the mechanical stimulation of microin-
jections induced dermis micro-inflammation with vasodi-
latation persisting 1 month after the last injection session.
However, as dermis thickening remained significant 3M
after the HA treatment only, we may hypothesise that by
contrast with the control, HA injections secondarily
induced the synthesis of dermis components such as
elastin and collagen which may contribute to dermis
thickness increase and be responsible for the remanence
of this effect. Collagen and elastin fibre synthesis acti-
vation and their potential renewal may also explain the
effect of HA on skin elastic parameters. The newly
formed fibres may be more compliant and their greater
Table 2 Dermis thickness measured by echography before (D0), and 1 month (1M) and 3 months (3M) after the last injection session of control
and HA filler in the FAS population
Dermis thickness, mm (mean ± SD) D0 1M % of change D0–1M 3M % of change D0–3M
HA filler 1.674 ± 0.214 1.731 ± 0.192 ?3.4* 1.741 ± 0.195 ?4**
Control 1.716 ± 0.225 1.759 ± 0.221 ?2.5* 1.735 ± 0.205 ?1.1
p value 0.122 – 0.842 – 0.290
Results are expressed as mean ± SD of 300 ultrasound images
* Comparison versus D0, p B 0.05
** Comparison versus D0, p B 0.01
 Comparison between control and HA treatments using ANCOVA analysis on the changes at 1 and 3M
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number and entanglement may reinforce the collagen and
elastin network, which is embedded in a proteoglycan and
glycosaminoglycan gel to form the dermis. The results of
a placebo-controlled study supports this hypothesis, since
it demonstrated that injections of stabilised HA into the
forearm skin significantly increased the synthesis of type
1 collagen in addition to profibrotic growth factors [20].
Another study, which observed an increase in the ech-
ogenicity of the subepidermal low-echogenic band by
ultrasound analysis after HA-based mesotherapy every
week for 4 weeks on the dorsum of the hands, also sug-
gested these changes may be related to an increased
density of dermal collagen fibres by fibroblast activation
resulting from treatment [13].
Another part of our study was the blinded assessment of
skin complexion radiance on standardised and calibrated
photographs. For this study, we developed a reliable and
reproducible method to objectively describe skin
Table 3 Skin complexion parameters evaluated by an expert panel before (D0) and 1 (1M) and 3 months (3M) after the end of mesotherapy
sessions in control and HA filler-treated hemifaces
Score (mean ± SD) D0 1M % of change D0–1M 3M % of change D0–3M
Complexion radiance
HA product 42.9 ± 9.4 44.6 ± 9.7 ?3.9 45.6 ± 11.4 ?6.2*
Control 43.2 ± 8.5 44.0 ± 9.2 ?2.1 42.2 ± 9.4 -2.3
p value 0.710 – 0.621 – 0.012
Yellow aspect
HA product 15.6 ± 8.8 13.8 ± 7.8 -11.3 13.8 ± 9.0 -11.4
Control 14.9 ± 7.8 13.1 ± 7.1 -12.1* 14.8 ± 8.7 -0.4
p value 0.201 – 0.782 – 0.175
Pink aspect
HA product 33.6 ± 11.2 35.6 ± 11.8 ?5.9 35.7 ± 12.1 ?6.2
Control 34.5 ± 13.3 36.8 ± 12.9 ?6.8* 35.0 ± 11.1 ?1.5
p value 0.243 – 0.637 – 0.403
Skin firmness
HA product 59.4 ± 14.1 58.6 ± 14.9 -1.3 59.8 ± 14.3 ?0.7
Control 61.1 ± 13.5 60.8 ± 13.8 -0.6 61.3 ± 14.1 ?0.2
p value 0.051 – 0.398 – 0.898
Hydration
HA product 48.7 ± 8.2 50.1 ± 9.3 ?2.9 50.2 ± 9.5 ?3.0
Control 47.9 ± 8.2 50.2 ± 8.3 ?4.6* 48.1 ± 9.2 ?0.4
p value  0.172 – 0.604 – 0.142
Luminosity
HA product 43.3 ± 9.2 44.7 ± 10.6 ?3.3 44.9 ± 11.1 ?3.8
Control 44.2 ± 9.7 45.1 ± 9.3 ?2.0 43.1 ± 9.5 -2.4
p value 0.184 – 0.985 – 0.102
Wrinkle quantity
HA product 26.0 ± 15.6 25.7 ± 15.6 -1.2 25.2 ± 15.1 -2.9
Control 24.4 ± 14.1 23.6 ± 14.3 -3.3 23.1 ± 14.7 -5.7
p value 0.086 – 0.396 – 0.330
Evenness
HA product 43.4 ± 12.7 44.5 ± 13.4 ?2.6 44.4 ± 14.7 ?2.3
Control 42.5 ± 10.7 42.8 ± 11.7 ?0.8 41.6 ± 11.9 -2.1
p value 0.297 – 0.501 – 0.157
Each score was calculated by using a 100 mm visual analogue scale and was expressed as the mean ± SD of the scores obtained by the 16
assessors. Improvement in pink aspect, skin firmness, hydration, luminosity and evenness was characterised by an increase of the score, that of
yellow aspect and wrinkle quantity by a decrease of the score
* Comparison versus D0, p B 0.05
 Comparison versus D0, p B 0.1
 Comparison between HA and control treatments using ANCOVA analysis on the changes at 1 and 3M
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complexion and in particular complexion radiance. To pre-
vent the panellists from being visually influenced by the skin
aspect of the non-treated areas, skin complexion was eval-
uated using randomised and cropped photographs corre-
sponding to the treated area of the cheeks and not to the
whole hemiface. With this method, we demonstrated for the
first time a positive effect of mesotherapy on skin com-
plexion radiance: HA microinjections induced a significant
and sustainable improvement in complexion radiance com-
pared with the control. Other skin complexion parameters
such as yellow aspect and hydration also tended to improve
after HA injections.
Finally, HA-based mesotherapy was considered globally
efficient by the subjects, as the percentage of the subjects
having perceived an improvement after each injection
session into the HA-treated hemiface was significantly
higher compared with the control-treated hemiface. Par-
ticularly, compared with the control, the percentage of
subjects having perceived slight to important improvement
1 and 3 months after the third injection of HA was more
than twice higher (60 vs 27.3 % and 51 vs 20 %, respec-
tively). HA injections were well tolerated, with a good to
excellent local tolerance in [85 % of cases.
Altogether, our results confirm those of previous studies
showing that non-reticulated HA-based mesotherapy can
improve skin hydration, firmness and viscoelastic proper-
ties. Although our study failed to show higher efficacy of
HA filler compared with placebo in improving parameters
of dermis mechanical behaviour and skin complexion, its
significant effect on skin complexion radiance and the fact
that E1 parameter was borderline significantly improved at
3M suggest that statistical significance might have been
achieved in a larger study population.
Only one non-comparative pilot study evaluating the
effect of three HA gel microinjection sessions on skin
elasticity and dermal thickness of 19 women has been
published [12, 16]. Using the cutometry and echography
methods, the authors showed a significant increase in all
skin elasticity parameters (gross and net elasticity, skin
extensibility, relaxation, fatigability and capacitance) in
both cheeks 1 and 3 months after the last injection [12, 16],
but they failed to show changes in skin thickness [16].
Another study evaluating the effect of microinjections of
a vitamin/HA solution by histology and electron micros-
copy of skin biopsies also failed to show changes in epi-
dermal and dermal thickness [4]. This absence of clinical
and histological modification may be due to a too small
amount of non-reticulated HA injected into the skin by
each micropuncture. The injection material was composed
of a 9:1 suspension of a multivitamin solution in a
Fig. 1 Perception by the subjects of HA-based mesotherapy efficacy
compared with the placebo 1 month after first, second and third
injection visits (2nd inj, 3rd inj and 1M) and 3 months after the third
injection (3M). The subject assessed the global product efficacy on
each hemiface by using a 5-point scale (worsening, stable, slight
improvement, moderate improvement, high improvement). Compar-
ison between HA and placebo effects was performed using the
Wilcoxon’s test, **p B 0.01
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non-conjugated HA gel, but unfortunately its concentration
was not indicated, precluding any comparison.
With regard to skin stiffness, Reuther et al. [16] sug-
gested an increase of this parameter, whereas we have
shown a significant decrease. Although microinjections
were performed at the level of the mid-dermis using a
mesotherapy technique, the study product was a non-ani-
mal stabilised HA (NASHA) gel and cutometry measure-
ments were performed with a probe with a 2 mm aperture
and by applying a 450 mbar negative pressure, i.e. exper-
imental conditions which allow epidermis and stratum
corneum evaluation. From a mechanical point of view,
dermis is the structure assumed to exert the greatest
influence on elastic mechanical properties of the skin [5,
22], a point which was recently confirmed by comparisons
between finite element models and elastographic mea-
surements [6]. We therefore considered that cutometry
measurements at the dermis level were more adapted to the
objectives of our study. This is why, according to Agache
et al. [3], we used a 6-mm aperture probe to specifically
measure dermal mechanical parameters and we coupled
these measurements with dermis thickness assessments by
echography to allow calculation of intrinsic cutometry
parameters [7]. In addition, our study was controlled
against physiological saline solution and the products were
injected randomly in the two hemifaces to avoid the
drawback of inter-individual variations.
In conclusion, this study objectively demonstrated the
efficacy and the tolerance of a non-cross-linked HA filler in
sustainably improving skin elastic parameters and com-
plexion radiance. In particular, we showed that intrader-
mally microinjected HA might be of value to improve
suppleness of ageing skin, inasmuch as injections are per-
formed by a trained physician with appropriate aseptic
measures. It might be worthy of a further study to assess
the role of HA in decreasing stiffness parameters and to
determine if its action is mainly mechanical or mediated by
the activation of dermis components synthesis by
fibroblasts.
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